Received by email:

File: CURE-News Release Int_update 18.07.18.docx

News Release
July 18, 2018
FOR IMMEDIATE RELEASE
BioCure Technology Inc. provides update on pre-clinical trial of Interferon-beta 1b.
Vancouver, British Columbia - BioCure Technology Inc. (CSE: CURE, OTCQB; BICTF) ("BioCure" or the "Company") is please
--->d to announce that its wholly owned subsidiary BiocurePharm Corporation ("BP Korea"), has implemented the preclinical 
--->trial of Interferon Beta 1b since late 2017 and is pleased to update shareholders on their progress. BP Korea announce
--->s that it has completed most of the toxicity testing and has developed MCB (Master Cell Bank) and WCB (Working Cell Ba
--->nk). Currently, BP Korea is in the middle of in-Vivo potency test. The Company has already produced 35,000 vials of In
--->terferon Beta 1b for their pre-clinical trial and stability test at the GMP manufacturing facility in Korea. 
BP Korea expects the pre-clinical trial shall be completed by the end of Q1, 2019 and will advance to clinical trial i
--->n 3Q 2019. 

Dr. Sang Mok Lee, CEO comments "We are making every effort to commercialize Interferon Beta, 1b, the first Biosimilar 
--->of the Company by 2021. BP Korea is in discussion with potential foreign partners to implement a clinical trial and pr
--->oduce Interferon Beta 1b in their countries through a partnership, once the pre-clinical trial is completed in Korea. 
--->We strongly believe that such partnerships could provide patients in those countries with much more affordable access 
--->to Interferon Beta."

About Biocure Technology Inc. 
Biocure Technology Inc. is a South Korean-based biopharmaceutical company, specializing in the development and commerc
--->ialization of CAR-T therapy for ALL(Acute lymphoblastic leukemia) and major biosimilar products. Biocure is in the pro
--->cess of preclinical trials of five major biosimilar products in South Korea, including interferon beta 1b, PEG-filgras
--->tim and ranibizumab, as well as CAR-T-cell therapy. Biocure is also developing a foot and mouth disease vaccine, and, 
--->a hair growth production product.

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ "Sang Mok Lee"
      CEO and Director

For further information, please contact: 

Biocure Technology Inc. Telephone: 604-609-7146

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" w
--->ithin the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limit
--->ed to, statements or information concerning the Company's proposed activities under the Agreement and the expectations
---> of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's curren
--->t assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown ri
--->sks and uncertainties and other factors which may cause actual results, performance or events to be materially differe
--->nt from those expressed or implied by such forward looking statements. Except as required pursuant to applicable secur
--->ities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the 
--->date hereof. More detailed information about potential factors that could affect financial results is included in the 
--->documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are caut
--->ioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") 
--->nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of 
--->this release.


.